7. Discontinued Operations (Tables)

6 Months Ended

Oct. 31, 2019

Discontinued Operations and Disposal Groups [Abstract]

Reconciliation discontinued operations

Gain on sale of research and development assets before income taxes (1)	$	1,000
Income tax expense		(261	)
Income from discontinued operations, net of tax	$	739

^[1]

[1] The gain on sale of research and development assets before income taxes was recorded in connection with the $1.0 million we received from Oncologie, Inc. ("Oncologie") under the September 2018 Asset Assignment and Purchase Agreement pursuant to which we sold to Oncologie our r84 technology, which included the assignment of certain licenses, patents and other assets useful and/or necessary for the potential commercialization of the r84 technology.